Trials / Unknown
UnknownNCT01565096
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- ikfe-CRO GmbH · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to glimepiride on beta cell function and the cardiovascular risk profile in patients previously treated with Metformin monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | Metformin 1000 mg BID |
| DRUG | Metformin | Metformin 1000 mg BID |
| DRUG | Vildagliptin | Vildagliptin 50 mg twice daily |
| DRUG | Glimepiride | Glimepiride at individual dose |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-11-01
- First posted
- 2012-03-28
- Last updated
- 2012-03-28
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01565096. Inclusion in this directory is not an endorsement.